Hofer & Associates. Inc Purchases New Position in AbbVie Inc. $ABBV

Hofer & Associates. Inc acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 3,135 shares of the company’s stock, valued at approximately $726,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie during the second quarter worth about $25,000. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie in the 2nd quarter valued at about $26,000. Spurstone Advisory Services LLC purchased a new position in AbbVie during the 2nd quarter worth approximately $28,000. Financial Gravity Companies Inc. acquired a new position in AbbVie during the second quarter worth approximately $36,000. Finally, Bear Mountain Capital Inc. lifted its stake in AbbVie by 480.6% in the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after buying an additional 173 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ABBV shares. Evercore ISI raised their target price on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Scotiabank assumed coverage on shares of AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price for the company. Raymond James Financial set a $256.00 target price on shares of AbbVie in a research note on Monday, November 3rd. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research report on Tuesday, November 4th. Finally, Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Price Performance

Shares of ABBV stock opened at $228.55 on Friday. The business’s fifty day moving average price is $226.66 and its 200 day moving average price is $213.48. The firm has a market capitalization of $403.94 billion, a PE ratio of 173.14, a P/E/G ratio of 1.30 and a beta of 0.36. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the company earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.